Join our daily newsletter At The Bell to receive exclusive market insights
- Resonance Health (RHT) contracted by Chinese company Hangzhou Zede Pharma-Tech to provide services for a clinical study into a treatment for patients with blood disorders
- The company says the Hangzhou Zede Pharma-Tech study will use its FerriScan medical device to measure and quantify liver-iron concentration of trial participants
- The contract marks the company’s entry into the Chinese market and is expected to last 14 months with a value of around US$200,000 (A$282,845)
- According to the company, around 30 to 40 million people in China are estimated to carry the particular blood disorder gene under investigation
- Shares in Resonance Health were up 3.13 per cent at the close of trading on Thursday at $0.16 each
Resonance Health (RHT) has been contracted by Chinese company Hangzhou Zede Pharma-Tech to provide services for a clinical study into a treatment for patients with blood disorders.
The company says the Hangzhou Zede Pharma-Tech study will use its FerriScan medical device to measure and quantify the liver-iron concentration of trial participants.
The contract marks the company’s entry into the Chinese market and is expected to last 14 months with a value of around US$200,000 (A$282,845). Under the terms of the deal, Hangzhou Zede Pharma-Tech may discontinue or extend the study at any time.
The study involves finding a treatment for patients aged 16 and over suffering from severe iron overload transfusion-dependent thalassemia, which is a type of blood disorder.
According to the company, around 30 to 40 million people in China are estimated to carry the particular blood disorder gene under investigation.
Shares in Resonance Health were up 3.13 per cent at the close of trading on Thursday at $0.16 each.
